Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 7102059
DNA molecules and polypeptides of Pseudomonas syringae Hrp pathogenicity island and their uses
granted -
US 7098197
Phosphonate compounds
granted -
US 7097998
AΞ²42 lowering agents
granted -
US 7097972
Method and composition for regulating apoptosis
granted -
US 7097991
Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
granted -
US 7098191
Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
granted -
US 7098306
Method and compositions for treating hepatocellular cancer
granted -
US 7097856
Dendrimeric support or carrier macromolecule
granted -
US 7097835
Immunoselective targeting agents and methods of use thereof
granted -
US 7098216
Thiazolopyrimidines useful as TNFΞ± inhibitors
granted -
US 7094413
Combined therapy for treatment of HIV infection
granted -
US 7094873
Polypeptide that interacts with heat shock proteins
granted -
US 7094772
Phosphonate compounds
granted -
US 7094758
Apoptotic compounds
granted -
US 7094597
Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
granted -
US 7094424
Cationic lipid compositions targeting angiogenic endothelial cells
granted -
US 7090864
Non-invasive gene targeting to ocular cells
granted -
US 7087413
Hyaluronan synthase gene and uses thereof
granted -
US 7087648
Methods for modulating macrophage proliferation using polyamine analogs
granted -
US 7087392
Antiproliferative SgK reagents and methods
granted -
US 7087582
Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
granted -
US 7083787
Yeast-dendritic cell vaccines and uses thereof
granted -
US 7083970
Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
granted -
US 7084208
N-halamine vinyl compounds and their polymeric biocides
granted -
US 7081474
Drugs to improve synaptic transmission
granted -
US 7081475
Wortmannin analogs and methods of using same
granted -
US 7078037
Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections
granted -
US 7078048
Method and compositions for treating rosacea
granted -
US 7078182
TAO protein kinase polypeptides and methods of use therefor
granted -
US 7078552
Combretastatin A-1 phosphate and combretastatin B-1 phosphate prodrugs
granted -
US 7078033
Urinary tract tissue graft compositions and methods for producing same
granted -
US 7074893
Methods and compositions for the treatment of diseases associated with signal transduction aberrations
granted -
US 7074938
Method for the synthesis of soritin compounds
granted -
US 7074900
Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin
granted -
US 7074554
Antibodies specific for NEBR1 and methods of use thereof
granted -
US 7074765
Synthetic peptide analogs of Arg-Pro-Pro-Gly-Phe as selective inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4
granted -
US 7070607
Bioabsorbable polymeric implants and a method of using the same to create occlusions
granted -
US 7070971
Glycosyl sulfotransferases GST-4Ξ±, GST-4Ξ², and GST-6
granted -
US 7070771
Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
granted -
US 7070973
Butyrylcholinesterase variants and methods of use
granted -
US 7071168
Anti-cancer compounds and methods related thereto
granted -
US 7070956
Peptides and derivatives thereof showing cell attachment, spreading and detachment activity
granted -
US 7070957
STARSβa muscle-specific actin-binding protein
granted -
US 7071318
Methods and compositions for stabilizing microtubules and intermediate filaments in striated muscle cells
granted -
US 7071293
Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt
granted -
US 7067254
Diagnosis and treatment of inflammation and hyperactive immune conditions
granted -
US 7067109
Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
granted -
US 7067111
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory